1-(5-amino-benzofuran-2-yl)-ethanone | 27408-34-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 1-(5-amino-benzofuran-2-yl)-ethanone
• 英文别名: 1-(5-aminobenzo[b]furan-2-yl)ethan-1-one；1-(5-amino-1-benzofuran-2-yl)ethanone
• CAS: 27408-34-0
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: SCXZAKMQIFBWMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(5-amino-benzofuran-2-yl)-ethanone 在 sodium hydroxide 、 硝酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-{4-[2-(2-Acetyl-benzofuran-5-ylamino)-pyrimidin-4-yl]-benzenesulfonyl}-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  A novel series of potent and selective IKK2 inhibitors

  摘要：

  A novel series of ammopyrimidine IKK2 inhibitors have been developed which show excellent in vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative potency and selectivity of these compounds has been rationalized using QSAR and structure-based modelling. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.047
• 作为产物：
  描述：

  2-乙酰基-5-硝基苯并[b]呋喃 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以54%的产率得到1-(5-amino-benzofuran-2-yl)-ethanone
  参考文献：
  名称：

  WO2006/73363

  摘要：

  公开号：

文献信息

• [EN] PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR X DU FOIE A BASE DE DERIVES PYRROLE-,5-DIONE
  申请人：ASTRAZENECA AB

  公开号：WO2005005417A1

  公开（公告）日：2005-01-20

  The present invention relates to certain novel compounds of the Formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及某些新颖化合物的公式（I），以及制备这些化合物的方法，它们在调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）方面的用途，以及在治疗和/或预防包括心血管疾病（如动脉粥样硬化）、炎症性疾病、阿尔茨海默病、脂质紊乱（失调脂质）以及与胰岛素抵抗、2型糖尿病和代谢综合征其他表现相关与否的临床病症方面的用途，以及它们的治疗用途的方法和含有它们的药物组合物。
• [EN] PROCESS FOR PREPARATION OF VILAZODONE AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE VILAZODONE ET DE SES INTERMÉDIAIRES
  申请人：GLENMARK PHARMACEUTICALS LTD ; GLENMARK GENERICS LTD

  公开号：WO2014087428A1

  公开（公告）日：2014-06-12

  Provided is a process for the preparation of vilazodone, its intermediate compounds and pharmaceutically acceptable salts thereof. Solvates of vilazodone and processes for their preparation are also provided. A process for the preparation of amorphous vilazodone hydrochloride is further provided.

  本发明提供了一种制备维拉唑酮、其中间化合物和药学上可接受的盐的过程。还提供了维拉唑酮的溶剂化物及其制备过程。此外，还提供了一种制备非晶态维拉唑酮盐酸盐的过程。
• Pyrrole-2,5-dione derivatives as liver x receptor modulators
  申请人：Boström Jonas

  公开号：US20060235015A1

  公开（公告）日：2006-10-19

  The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及一些新的I型化合物，以及制备这些化合物的方法，它们在调节核激素受体肝X受体(LXR)α（NR1H3）和/或β（NR1H2）方面的效用，以及在治疗和/或预防包括心血管疾病（如动脉粥样硬化）、炎症性疾病、阿尔茨海默病、脂质紊乱（无论是否与胰岛素抵抗有关）、2型糖尿病和代谢综合征的其他表现等临床疾病中的应用，以及它们的治疗用途的方法和含有它们的制药组合物。
• Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators
  申请人：Bostrom Jonas

  公开号：US20080255122A1

  公开（公告）日：2008-10-16

  The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及公式(I)的某些新化合物的制备方法，它们在调节核激素受体肝X受体(LXR)α (NR1H3)和/或β (NR1H2)以及治疗和/或预防包括心血管疾病（如动脉硬化）、炎症性疾病、阿尔茨海默病、脂质异常（是否与胰岛素抵抗有关）、2型糖尿病和代谢综合征的其他表现等临床疾病中的应用，以及它们的治疗用途的方法和含有它们的制药组合物。
• DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR
  申请人：Bostrom Jonas

  公开号：US20100016321A1

  公开（公告）日：2010-01-21

  The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及公式（I）的某些新化合物，以及制备这些化合物的过程，它们在调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）以及治疗和/或预防包括心血管疾病（如动脉粥样硬化）、炎症性疾病、阿尔茨海默病、脂质异常（是否伴随胰岛素抵抗）、2型糖尿病和代谢综合征的其他表现等临床疾病方面具有用途，以及它们的治疗使用方法和包含它们的制药组合物。